Drug Resistance of Mycobacterium tuberculosis to Linezolid and Delamanid: A Case report from Bukavu, Democratic Republic of Congo
The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South-Kivu in Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about potential global spread and poor outcome of the WHO recommended oral treatment regimens and highlights the need for urgent roll-out of DST.